- Press Release -

Rockville, Md. The global breast cancer diagnostics market is set to expand at a 4.7% CAGR and pass US$ 2 Bn by 2022, according to Fact.MR, as rising case volumes and better instruments reshape detection. Hybrid diagnostic tools that improve accuracy are pulling the market forward, while personalised, risk-adapted approaches and newer imaging such as tomosynthesis address the inconclusive results that have dogged conventional mammography.

BRCA leads by test type, hospital-associated labs handle most testing, and North America carries the market. Growth, though, is broadening as research settings scale up faster than the market as a whole.

Tests, Settings and Regions

BRCA remains the dominant test and HER2 the second largest, while CA tests post the highest CAGR, followed by ER and PR, though both stay modest in revenue and EGFR mutation testing smaller still. By setting, hospital-associated labs generate the largest revenue, ahead of independent diagnostic laboratories, and cancer research institutes grow the quickest, adding US$ 107.3 Mn in absolute opportunity between 2017 and 2022.

North America stays the largest region and is set to pass US$ 800 Mn by 2022, with Europe in second place, while Japan and the Middle East and Africa expand slowly.

Better Tools, Persistent Gaps

The clinical picture explains the demand. Breast cancer remains the most common cancer among women, and a growing older population points to more cases and a sharper need for early, reliable detection. Improved instruments help, but a shortage of skilled and trained personnel is holding back how fast diagnosis can scale.

Suppliers and Their Playbook

The field brings together imaging and molecular diagnostics majors.

• Siemens AG, Myriad Genetics, Inc., Roche Holding AG, Illumina, Inc., Epigenomics AG, Abbott Laboratories, Thermo Fischer Scientific, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., AstraZeneca plc, and Quest Diagnostics Incorporated are among the key players in the report.

Reading the Market for Decisions

For diagnostics firms, growth favours those advancing hybrid instruments and risk-adapted testing. Investors get a market with durable clinical demand and moderate growth. Procurement and lab teams can plan around hospital labs leading demand, BRCA carrying volume, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global breast cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the breast cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.